Your browser doesn't support javascript.
loading
[IMATINIB INDUCED EDEMA].
Olshanskiy, Dmitriy; Ben Varon, Hen; Mouallem, Meir.
Affiliation
  • Olshanskiy D; Department of Medicine E, Sheba Medical Center Tel-Hashomer, affiliated to Faculty of Medicine, Tel-Aviv University Israel.
  • Ben Varon H; Department of Medicine E, Sheba Medical Center Tel-Hashomer, affiliated to Faculty of Medicine, Tel-Aviv University Israel.
  • Mouallem M; Department of Medicine E, Sheba Medical Center Tel-Hashomer, affiliated to Faculty of Medicine, Tel-Aviv University Israel.
Harefuah ; 163(6): 397, 2024 Jun.
Article in He | MEDLINE | ID: mdl-38884296
ABSTRACT

INTRODUCTION:

Imatinib is a tyrosine kinase inhibitor and is used for the treatment of chronic myeloid leukemia (CML) since 2002. We present a patient who suffered from fluid retention and periorbital edema secondary to this drug.
Subject(s)
Search on Google
Add to My VHL
Print
XML
PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Protein Kinase Inhibitors / Edema / Imatinib Mesylate / Antineoplastic Agents Limits: Female / Humans / Male / Middle aged Language: He Journal: Harefuah Year: 2024 Document type: Article Country of publication:
Search on Google
Add to My VHL
Print
XML
PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Protein Kinase Inhibitors / Edema / Imatinib Mesylate / Antineoplastic Agents Limits: Female / Humans / Male / Middle aged Language: He Journal: Harefuah Year: 2024 Document type: Article Country of publication: